Markets US
Moderna boosted its 2026 revenue growth guidance to 15%-25%, up from a prior outlook of up to 10%, after third-quarter revenue surged 29% to $1.31 billion, exceeding analyst expectations.
Moderna reported third-quarter revenue of $1.31 billion, a 29% increase from $885.1 million expected, driven by new product launches, geographic diversification, and strong performance from its next-generation mRNA COVID-19 vaccine and standalone flu shot. CEO Stéphane Bancel highlighted these factors as key to the revised full-year 2026 revenue growth guidance of 15%-25%, up from a prior outlook of up to 10%. The company’s earnings per share (EPS) reached 38 cents, compared to an expected loss of $1.25, while net income for Q3 was $162 million, versus a net loss of $200 million in the same period last year. U.S. revenue totaled $780 million, with international markets contributing $533 million. Moderna’s stock rose 3% in premarket trading following the results, marking a 700% surge this year due to optimism about its mRNA technology.
The revised revenue guidance reflects Moderna’s ability to leverage new product launches and geographic expansion into Canada, the U.K., and Asia, alongside cost reductions that improved profitability. However, the stock’s volatility after leaked cancer vaccine trial data highlighted market sensitivity to unverified information. While the next-generation mRNA COVID-19 vaccine received U.S. approval in May 2025, limited initial launches of new vaccines, such as the flu shot in 2026, could delay full-year revenue contributions from these products.
Moderna’s expansion into Canada, the U.K., and Asia provides new revenue streams and reduces reliance on U.S. markets. The success of its mRNA vaccines could solidify its leadership in vaccine innovation. However, investor confidence remains vulnerable to negative reactions to unverified data, as seen in the stock’s decline following the leak of cancer vaccine trial details. The company and Merck will present late-stage cancer vaccine data at a European medical conference, though the data was partially leaked before the event.
Moderna and Merck will present late-stage cancer vaccine data at a European medical conference, though the data was partially leaked before the event. No other specific future events are mentioned.
Moderna’s revised revenue outlook signals strong product momentum, but market uncertainty persists due to leaked trial data. Sustained geographic and product diversification will determine long-term growth.
Topics: Moderna, MRNA Vaccines, Biotech Sector, Financial Results, Global Expansion, Vaccine Innovation, Stock Performance, Cancer Vaccine Data
#Moderna #mRNAtech #BiotechSector #FinancialResults #GlobalExpansion #VaccineInnovation #CancerVaccineData
Source: CNBC
Post a Comment
Post a Comment